Significant number of drugs on the market not yet fully approved
A large number of drug manufacturers are failing to complete the FDA’s Accelerated Approval Program, meaning not all available drugs are fully approved, finds a study.
BALTIMORE, MD, November 12, 2024 – New research in the INFORMS journal Manufacturing & Service Operations Management is guiding the development of more inclusive and efficient electricity markets. The work demonstrates how aggregating small-scale, distributed energy resources (DERs) like solar panels can effectively balance the power of large utility companies.
Donald Trump's return to the White House is likely to usher in sweeping changes that affect retailers such as Walmart, Target, and Costco — from new tariffs to tax cuts and a new regulatory environment.
An audio journey of how data and analytics save lives, save money and solve problems.
Ashley Smith
Public Affairs Coordinator
INFORMS
Catonsville, MD
[email protected]
443-757-3578
Explore our resources for multiple topics including:
A large number of drug manufacturers are failing to complete the FDA’s Accelerated Approval Program, meaning not all available drugs are fully approved, finds a study.
The Food and Drug Administration (FDA) Accelerated Approval Program was created in 1992 to considerably speed up the ability to bring certain new drugs to market. Further research to be revealed in upcoming issues of the INFORMS journal Manufacturing & Service Operations Management shows numerous drug producers are failing to finish the approval course of, meaning a significant number of drugs on the market will not be but approved.
Colorectal cancer (CRC) is the second leading cause of death due to cancer in the United States. Regular medical screening can be effective in detection and treatment, but only about 40 percent of the population is doing it. So why would people risk a potentially deadly diagnosis? Research points to significant appointment delays among some of the most effective tests, such as a colonoscopy.
CATONSVILLE, MD, August 26, 2019 – The Food and Drug Administration’s (FDA) Accelerated Approval Program was created in 1992 to significantly accelerate the ability to bring certain new drugs to market. New research published in the INFORMS journal Manufacturing & Service Operations Management reveals a large number of drug manufacturers are failing to complete the approval process, meaning a significant number of drugs on the market are not yet fully approved.
Hospitals can seem like confusing, chaotic places for patients, even when the employees are following well-established protocols and resource management techniques. But there is always room for improvement. That’s the goal behind the research of Hummy Song, Wharton professor of operations, information and decisions, who focuses on improving the performance of health care delivery systems.
OR/MS Today is the INFORMS member magazine that shares the latest research and best practices in operations research, analytics and the management sciences.
Access OR/MS Today MagazineAnalytics magazine showcases articles and research reports based on big data, AI, machine learning, data analytics and other new-age technologies.
Access Analytics Magazine